Investors
CSL is a global biotech leader. Our dedicated management and employees are driven to fulfill our promise to patients to deliver life-saving and life-improving therapies that help many thousands of people live full lives.
Investor InformationSearch Results
906 results found-
Total LTI Reward LTI Growth in Received (valued Value (due to 2023 Total Fixed 2023 STI LTI Vested in Total Reward at grant date) share price Executive Received US$2 US$3 2023 US$4 Reward US$ US$5 growth) US$6 Period Earned 2023 2023 2019 - 2023 2019 - 2023 2019 - 2023 2019 - 2023 P McKenzie 1,340,311 1,376,890 1,634,350 4,351,551 1,446,967 187,383 J Linton 1,044,351 946,395 1,003,581 2,994,327 901,287 102,294 Former Executive KMP P Perreault7 1,354,165 1,537,182 3,148,999 6,040,346 2,806,440 342,559
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
39 The value at grant date has been determined by the share price at the close of business on the grant date of 22 August 2019 being A$238.86 and for C Hewson the share price at the close of business on 20 February of A$338.68 multiplied by the number of Rights granted during 2020.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
19 The face value is calculated using a share price of A$227.31 being the share price on the date of grant - 1 September 2018.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
calculated based on independent and valuation Performance Options - Increase the proportion of remuneration linked to long term share price growth - Share price appreciation from grant and consistent achievement of individual performance metrics.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
33 The face value is calculated using a share price of A$133.96 being the share price on the date of grant - 1 October 2017.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
21 The number of Options is calculated based on an assessment of the fair market value of the instruments in accordance with the accounting 19 The face value is calculated using a share price of A$107.00 being the share price on the date of grant.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
c) establish procedures for dealing in CSL Securities and Other Securities that provide protection to both CSL and Personnel against the misuse of unpublished price-sensitive information which could result in material criminal and/or civil penalties
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/securities-dealing-policy.pdf -
to the ASX information about CSL that a reasonable person from trading CSL shares when they are in possession would expect to have a material effect on the price or value of price-sensitive information that is not generally A of CSL securities.
https://www.csl.com/-/media/shared/documents/one-csl/crbp-languages/csl_crbp2021_english_external.pdf -
PURPOSE AND SCOPE CSL Limited (CSL) has obligations under the Corporations Act 2001 (Cth) (Corporations Act) and the ASX Listing Rules to keep the market fully informed of information that may have a material effect on the price or value of CSL securities.
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/continuous-disclosure-policy.pdf -
The principles in the OECD Transfer Pricing Guidelines will be adopted when determining the appropriate transfer price for transactions between International Related Parties.
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2022-23.pdf